SCHEMBL13629418

SCHEMBL13629418

CCc1ccc(NS(=O)(=O)c2cccc(Cl)c2)cc1F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.61
PGR P06401 11/20 0.60
LMNA P02545 2/20 0.56
MAPT P10636 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
ALDH1A1 P00352 1/20 0.56
KIT P10721 1/20 0.53
HDAC3 O15379 1/20 0.51
HDAC4 P56524 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC7 Q8WUI4 1/20 0.51
HDAC2 Q92769 1/20 0.51
HDAC10 Q969S8 1/20 0.51
HDAC11 Q96DB2 1/20 0.51
HDAC8 Q9BY41 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
HDAC9 Q9UKV0 1/20 0.51
HDAC5 Q9UQL6 1/20 0.51
ALOX15 P16050 1/20 0.50
KDR P35968 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13629298 0.88 MEN1 (0.49) PKMPGRLMNAMAPTALDH1A1
SCHEMBL13853000 0.85 KMT2A (0.55) PKMPGRLMNAMAPTALDH1A1
SCHEMBL13852925 0.85 PKM (0.75) PKMPGRLMNAMAPTTDP1
SCHEMBL13629403 0.85 CES1 (0.58) PKMLMNAMAPTTDP1ALDH1A1
SCHEMBL16325530 0.84 PKM (0.77) PKMPGRLMNAMAPTTDP1
SCHEMBL13629409 0.82 PGR (0.60) PKMPGRLMNAALDH1A1HDAC3
SCHEMBL13629410 0.82 HSD17B2 (0.61) PGRLMNAMAPTHDAC1HDAC8
SCHEMBL13852945 0.82 PGR (0.64) PKMPGRLMNAMAPTTDP1
SCHEMBL13629427 0.81 ALDH1A1 (0.54) PKMLMNAMAPTALDH1A1
SCHEMBL13615211 0.81 PKM (0.60) PKMPGRLMNAMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK PKM 446/4885PGR 1648/4885LMNA 2608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.